PET- FDG en cáncer oculto primario de mama

Article information

Resumen

La tomografía por emisión de positrones es una técnica de eficacia comprobada en la detección de la afección locoregional y a distancia del cáncer de mama.

Presentamos el caso de dos pacientes con afección axilar secundaria a cáncer oculto de mama, en los que la tomografía por emisión de positrones con 18-fluoro-2-desoxi-D-glucosa (PET-FDG) permitió identificar la localización del tumor primario y por tanto efectuar un tratamiento quirúrgico posterior.

Analizamos, además, la utilidad de la PET-FDG y de los métodos de imagen convencionales en el diagnóstico de esta entidad.

Palabras clave:

Carcinoma primario oculto de mama

Tomografía de emisión por positrones (PET)

18-fluoro-2- desoxi-D-glucosa (FDG)

Positron emission tomography (PET) has been proved to be effective in detecting locoregional and distant breast cancer. We report two patients with axillary involvement secondary to occult primary breast carcinoma. The use of PET with fluorine-18-fluorodeoxyglucose (FDG) enabled identification of the primary breast tumor and the appropriate surgical treatment to be given. In addition, we analyze the usefulness of PET-FDG and that of conventional imaging methods in the diagnosis of this entity.

Key words:

Occult primary breast cancer

Positron emission tomography (PET)

18-fluoro-2-deoxy-D-glucose (FDG)

Full text is only aviable in PDF

Bibliografía

[1.]

M. Merson, S. Andreoia, V. Galimberti, R. Bufalino, S. Marchini, et al.

Breast carcinoma presenting as axillary metastases without evidence of a primary tumor.

Cancer, 70 (1992), pp. 504-508

Medline

[2.]

B. Van Ooijen, M. Bontenbal, S.C. Henzen-Logmans, P.C. Koper.

Axillary nodal metastases from an occult primary consistent with breast carcinoma.

Br J Surg, 80 (1993), pp. 1299-1300

Medline

[3.]

G.H. Sakarofas, A.G. Tsiotou.

Occult breast cancer: a challenge from a surgical perspective.

Surg Oncol, 8 (1999), pp. 27-33

Medline

[4.]

W.S. Halsted.

The results of radical operations for the cure of carcinoma of the breast.

Ann Surg, 46 (1907), pp. 1-19

Medline

[5.]

P. Rigo, P. Paulus, B.J. Kaschten, R. Hustinx, T. Bury, G. Jerusalem, et al.

Oncological applications of positron emission tomography with fluorine-18 florodeoxyglucose.

Eur J Nucl Med, 23 (1996), pp. 1641-1674

Medline

[6.]

N.Y. Tse, C.K. Hoh, R.A. Hawkins, M.J. Zinner, M. Dahlbom, Y. Choi, et al.

The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease.

Ann Surg, 216 (1992), pp. 27-34

Medline

[7.]

E.F. Block, M.A. Meyer.

Positron emission tomography in diagnosis of occult adenocarcinoma of the breast.

Am Surg, 64 (1998), pp. 906-908

Medline

[8.]

C.R. Scoggins, J.V. Vitola, M.P. Sandler, J.B. Atkinson, M. Frexes-Steed.

Occult breast carcinoma presenting as an axillary mass.

Am Surg, 65 (1999), pp. 1-5

Medline

[9.]

V.P. Jackson.

What is the role of sonographic breast imaging for detecting occult cancer in a patient with a strong family history of breast cancer and mammographically dense breasts without obvious masses?.

AJR Am J Roentgenol, 165 (1995), pp. 1004

http://dx.doi.org/10.2214/ajr.165.4.7676946 | Medline

[10.]

V.P. Jackson.

The role of US in breast imaging.

Radiology, 177 (1990), pp. 305-311

http://dx.doi.org/10.1148/radiology.177.2.2217759 | Medline

[11.]

Kopans DB. “Early” breast cancer detection using techniques other than mammography. AJR Am J Radiol 198; 143: 465-468

[12.]

P.J. Sianetz, R. Jain, J.L. Kline, K.A. McCarthy, J.L. Goldenberg, W.B. Edmister.

CT-guided preoperative needle localization of MR imagingdetected mammographically occult lesions.